Abstract
The coronavirus pandemic is one of the most significant public health events in recent history. Currently, no specific treatment is available. Some drugs and cell-based therapy have been tested as alternatives to decrease the disease’s symptoms, length of hospital stay, and mortality. We reported the case of a patient with a severe manifestation of COVID-19 in critical condition who did not respond to the standard procedures used, including six liters of O 2 supplementation under a nasal catheter and treatment with dexamethasone and enoxaparin in prophylactic dose. The patient was treated with tocilizumab and an advanced therapy product based on umbilical cord-derived mesenchymal stromal cells (UC-MSC). The combination of tocilizumab and UC-MSC proved to be safe, with no adverse effects, and the results of this case report prove to be a promising alternative in the treatment of patients with severe acute respiratory syndrome due to SARS-CoV-2.
Keywords: COVID-19; mesenchymal stromal cells; tocilizumab; umbilical cord.
【저자키워드】 COVID-19, Tocilizumab, Mesenchymal stromal cells, Umbilical cord, 【초록키워드】 Dexamethasone, Treatment, public health, SARS-CoV-2, coronavirus, pandemic, therapy, Mortality, drug, Symptoms, Case report, adverse effects, Patient, Combination, Safe, Hospital stay, prophylactic dose, stromal cell, acute respiratory syndrome, nasal catheter, critical condition, specific treatment, event, decrease, tested, reported, the disease, treated, respond, standard procedure, UC-MSC, umbilical, 【제목키워드】 Tocilizumab, stromal cell, report, Combined,